Hologic
HOLOGIC INC
Key figures
Period 2024-09-29 to 2025-09-27ConsolidatedU.S. GAAP
RevenueDisclosed
US$4.1B
Operating marginCalculated
17.4%
Net assets to total assetsCalculated
56.0%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
17.4%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-7.6%
Capital efficiency
★★★☆☆position among all companies
11.2%
Revenue and profit
Performance, financial position and capital allocation
Hologic
Recent performance trends
Hologic
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$5.6 billion | US$4.9 billion | US$4.0 billion | US$4.0 billion | US$4.1 billion |
| Operating income | US$2.5 billion | US$1.6 billion | US$0.7 billion | US$0.9 billion | US$0.7 billion |
| Net income | US$1.9 billion | US$1.3 billion | US$0.5 billion | US$0.8 billion | US$0.6 billion |
| Total assets | US$8.9 billion | US$9.1 billion | US$9.1 billion | US$9.2 billion | US$9.0 billion |
| Shareholders' equity | US$4.2 billion | US$4.9 billion | US$5.0 billion | US$5.1 billion | US$5.0 billion |
| Net cash provided by (used in) operating activities | US$2.3 billion | US$2.1 billion | US$1.1 billion | US$1.3 billion | US$1.1 billion |
| Net cash provided by (used in) investing activities | US$-1.3 billion | US$-0.2 billion | US$-0.2 billion | US$-0.8 billion | US$-0.5 billion |
| Net cash provided by (used in) financing activities | US$-0.5 billion | US$-0.8 billion | US$-0.5 billion | US$-1.1 billion | US$-0.8 billion |
| Cash and cash equivalents | US$1.2 billion | US$2.3 billion | US$2.7 billion | US$2.2 billion | US$2.0 billion |
Revenue scale in the same industry
Hologic
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 26 companies
- 30 IlluminaFY Dec 2025 US$4.3B
- 31 FortiveFY Dec 2025 US$4.2B
- 32 HologicThis companyFY Sep 2025 US$4.1B
- 33 The Cooper CompaniesFY Oct 2025 US$4.1B
- 34 Align TechnologyFY Dec 2025 US$4.0B
- … 9 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$58.80 million | Consolidated | Disclosed |
| Cash and cash equivalents | US$2.0 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.8 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.5 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$1.1 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.3 billion | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$5.0 billion | Consolidated | Disclosed |
| Net assets | US$5.0 billion | Consolidated | Disclosed |
| Net sales | US$4.1 billion | Consolidated | Disclosed |
| Operating income | US$0.7 billion | Consolidated | Disclosed |
| Net income | US$0.6 billion | Consolidated | Disclosed |
| Total assets | US$9.0 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.8 billion | Consolidated | Disclosed |
| Operating margin | 17.4% | Consolidated | Calculated |
| Net assets to total assets | 56.0% | Consolidated | Calculated |
| Net margin | 13.8% | Consolidated | Calculated |
| Return on equity | 11.2% | Consolidated | Calculated |